Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active. The method can include, for example, obtaining a MenaINV score assessed by fine needle aspiration in the same tissue. The present invention can be used as both a prognostic for dissemination and a predictive end point for identification and validation of dissemination inhibitors/anti-metastasis drugs.
Disclosed herein are the systems, devices and methods for treating cancer and metastasis using low energy immune priming. The low energy immune priming includes administering immunopriming energy. The low energy immune priming can be combined with an adjunct therapy.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
3.
LOW INTENSITY FOCUSED ULTRASOUND FOR TREATING CANCER AND METASTASIS
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
G06T 19/00 - Manipulating 3D models or images for computer graphics
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
G06T 7/68 - Analysis of geometric attributes of symmetry
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
5.
THROMBOPOIETIN MIMETIC FOR USE IN THE TREATMENT OF ACUTE LIVER FAILURE
A method of treating patients suffering from acute liver failure is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thrombopoietin (TPO) compound alone or combined with another agent as described in the specification. A method of treating patients suffering from acetaminophen overdose is also disclosed. The method comprises administering to a patient in need of treatment an effective amount of a TPO compound alone or combined with another agent as described in the specification.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
6.
GENERATING IMAGE DATA FOR THREE-DIMENSIONAL TOPOGRAPHICAL VOLUMES, INCLUDING DICOM-COMPLIANT IMAGE DATA FOR SURGICAL NAVIGATION
Methods of generating image data for three-dimensional topographical volumes, and associated systems, devices, and methods are disclosed herein. In one embodiment, a method of generating a volumetric dataset for surgical navigation includes obtaining a three-dimensional topographical volume of a patient representing one or more surface contours of patient anatomy. The method can further include voxelating the three-dimensional topographical volume to generate a three-dimensional voxelated volume, and volume rendering the three-dimensional voxelated volume into a sequence of two-dimensional cross-sectional images that can each include a two-dimensional slice of the three-dimensional voxelated volume. The method can include conforming the sequence to an imaging standard (e.g., the DICOM Standard). In some embodiments, a difference between actual patient anatomy and desired patient anatomy at a location a probe contacts the patient can be displayed by a surgical navigation system once a three-dimensional volume reconstructed from the conformed sequence is registered to the patient.
Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such polypeptides, expression vectors and cells comprising such nucleic acids, and methods of producing the polypeptides comprising a thrombopoietin domain and a Flt3 ligand domain. The administration of a fusion polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain to a subject may treat and reduce the symptoms of hematopoietic failure, including thrombopenia, and/or acute radiation syndrome.
Johannes Gutenberg University (JGU) Medical Center (Germany)
Inventor
Tomer, Yaron
Faustino, Larissa C.
Kahaly, George J.
Abstract
Methods of predicting response of a subject in need of immunosuppressant therapy to a Cluster of differentiation 40 (CD40)-targeted treatment are disclosed. The methods permit treating the subject with a treatment most likely to show a favorable response.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
9.
DENDRITIC CELL ACTIVATING THERAPY AS AN ADJUNCT TO RADIATION THERAPY
Provided herein are methods relating to administering a dendritic cell activating therapy as an adjunct to radiation therapy or an energy-based therapy for treating a tumor or cancer in an individual.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07C 49/80 - Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
C07C 49/807 - Ketones containing a keto group bound to a six-membered aromatic ring containing halogen all halogen atoms bound to the ring
C07C 49/825 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
C07C 233/33 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 323/22 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
C07D 207/04 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 207/325 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
C07D 295/112 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 333/22 - Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
42 - Scientific, technological and industrial services, research and design
Goods & Services
Research and development in the fields of biotechnology and biomanufacturing, namely, development of next-generation drugs in the nature of gene-therapy, cell-based therapies and biologics for use in humans
Methods of increasing progenitor cell production are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic is used to increase production of at least one cell selected from a stem cell, a progenitor cell or an endothelial cell in the bone marrow of non- irradiated subjects.
Methods of increasing progenitor cell production are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic is used to increase production of at least one cell selected from a stem cell, a progenitor cell or an endothelial cell in the bone marrow of non- irradiated subjects.
Provided herein are CD25 chimeric antigen receptors and compositions and methods for using the same. Methods for using CD25 chimeric antigen receptors provided herein include, for example, methods of treatment, methods of enhancing the immune system in a subject, and methods of killing a target cell or a population of target cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods and systems are provided for treating a cancer in a subject, the method comprising providing an ablative dose of radiation therapy to a first region comprising the cancer followed by a sub-ablative dose to a second region, wherein the sub-ablative dose is administered within 1 hour to 4 days after the ablative dose.
The present technology is directed to identifying neutrophil extracellular traps (NETs) in blood. For example, the present technology provides artificial intelligence systems, architectures, and/or programs that can rapidly and/or automatically identify and/or enumerate NETs in peripheral blood smears, CBC scattergrams, and the like. The artificial intelligence architectures can be integrated into current automated imaging and/or analysis systems (e.g., automated imaging systems for performing cell blood counts (CBC)). The artificial intelligence architectures can also be integrated into another computing device, such as a mobile device.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/84 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using probabilistic graphical models from image or video features, e.g. Markov models or Bayesian networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
18.
METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES
JOHANNES GUTENBERG UNIVERSITY (JGU) MEDICAL CENTER (Germany)
Inventor
Tomer, Yaron
Faustino, Larissa C.
Kahaly, George J.
Abstract
Methods of predicting response of a subject in need of immunosuppressant therapy to a Cluster of differentiation 40 (CD40)-targeted treatment are disclosed. The methods permit treating the subject with a treatment most likely to show a favorable response.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
19.
DENDRITIC CELL ACTIVATING THERAPY AS AN ADJUNCT TO RADIATION THERAPY
Provided herein are methods relating to administering a dendritic cell activating therapy as an adjunct to radiation therapy or an energy-based therapy for treating a tumor or cancer in an individual.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided herein are methods relating to administering a dendritic cell activating therapy as an adjunct to radiation therapy or an energy-based therapy for treating a tumor or cancer in an individual.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Methods and compositions are disclosed for reducing neuropathy or ototoxicity associated with chemotherapeutic agents by administering one or more enol compounds to a subject.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A sterilizable device comprising electromagnetic transponders separated from one another by a flexible spacer material enclosed within radiofrequency-transparent sterilizable tubing for target tracking during prostate treatments, and method of use thereof.
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A method of treating metastases (e.g., brain metastases) in a patient with cancer (e.g., lung cancer) and at risk for metastases, exhibiting symptoms of metastases, or identified with metastases includes administering a therapeutically effective amount of a RICTOR inhibitor for the treatment of metastases. A method of reducing resistance to an EGFR, MET or AKT inhibitor in a cancer patient being administered the EGFR. MET or AKT inhibitor comprises co-administering a therapeutically effective amount of a RICTOR inhibitor and the EGFR, MET or AKT inhibitor. RICTOR inhibitors include compounds of formulas I-IV.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
25.
METHODS OF TREATING CANCER WITH DENDRITIC CELL MOBILIZING AGENTS
Methods of treating cancer comprising administering to patients a dendritic cell mobilizing agent (e.g., Flt3 ligand) in combination with radiation and/or immunoregulatory agents (e.g., checkpoint inhibitors), are disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Methods and systems are provided for treating a cancer in a subject, the method comprising providing an ablative dose of radiation therapy to a first region comprising the cancer followed by a sub-ablative dose to a second region, wherein the sub-ablative dose is administered within 1 hour to 4 days after the ablative dose.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
Provided herein are CD25 chimeric antigen receptors and compositions and methods for using the same. Methods for using CD25 chimeric antigen receptors provided herein include, for example, methods of treatment, methods of enhancing the immune system in a subject, and methods of killing a target cell or a population of target cells.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and/or treatment of TID.
G06T 19/00 - Manipulating 3D models or images for computer graphics
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
G06T 7/68 - Analysis of geometric attributes of symmetry
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
The present technology is directed to identifying neutrophil extracellular traps (NETs) in blood. For example, the present technology provides artificial intelligence systems, architectures, and/or programs that can rapidly and/or automatically identify and/or enumerate NETs in peripheral blood smears, CBC scattergrams, and the like. The artificial intelligence architectures can be integrated into current automated imaging and/or analysis systems (e.g., automated imaging systems for performing cell blood counts (CBC)). The artificial intelligence architectures can also be integrated into another computing device, such as a mobile device.
Disclosed herein are the systems, devices and methods for treating cancer and metastasis using low energy immune priming. The low energy immune priming includes administering immunopriming energy. The low energy immune priming can be combined with an adjunct therapy.
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
32.
METHODS FOR MITIGATING LIVER INJURY AND PROMOTING LIVER HYPERTROPHY, REGENERATION AND CELL ENGRAFTMENT IN CONJUNCTION WITH RADIATION AND/OR RADIOMIMETIC TREATMENTS
Methods and kits for mitigating liver injury and promoting liver regeneration and engraftment in a subject treated with a targeted radiation therapy are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced liver diseases and promote beneficial effects for liver regeneration and engraftment in conjunction with radiation or radiomimetics.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
33.
METHODS FOR MITIGATING LIVER INJURY AND PROMOTING LIVER HYPERTROPHY, REGENERATION AND CELL ENGRAFTMENT IN CONJUNCTION WITH RADIATION AND/OR RADIOMIMETIC TREATMENTS
Methods and kits for mitigating liver injury and promoting liver regeneration and engraftment in a subject treated with a targeted radiation therapy are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced liver diseases and promote beneficial effects for liver regeneration and engraftment in conjunction with radiation or radiomimetics.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
34.
METHODS FOR MITIGATING LIVER INJURY AND PROMOTING LIVER HYPERTROPHY, REGENERATION AND CELL ENGRAFTMENT IN CONJUNCTION WITH RADIATION AND/OR RADIOMIMETIC TREATMENTS
Methods and kits for mitigating liver injury and promoting liver regeneration and engraftment in a subject treated with a targeted radiation therapy are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced liver diseases and promote beneficial effects for liver regeneration and engraftment in conjunction with radiation or radiomimetics.
Methods and compositions are disclosed for reducing neuropathy or ototoxicity associated with chemotherapeutic agents by administering one or more enol compounds to a subject.
Methods are provided for measuring the activity of TMEM sites in a tumor comprising measuring a transient increase in permeability of blood vessels at TMEM sites that allows tumor cells to enter the blood vessels, wherein permeability is measured using a modality selected from the group consisting of MRI, PET, CT, and SPECT, and wherein a transient increase in permeability indicates that a TMEM site is active. The method can include, for example, obtaining a MenaINV score assessed by fine needle aspiration in the same tissue. The present invention can be used as both a prognostic for dissemination and a predictive end point for identification and validation of dissemination inhibitors/anti-metastasis drugs.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The Board of Trustees of the University of Arkansas (USA)
The Kitasato Institute (Japan)
Montefiore Medical Center (USA)
National University Corporation Kagawa University (Japan)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert C.
Nishi, Nozomu
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
A61Q 7/00 - Preparations for affecting hair growth
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
Catheters and methods for controlling bleeding in airways and for occlusion of airways are provided that allow a bronchoscope to be withdrawn from the airway while an inflated balloon catheter remains in position in the airway, for example at a site of airway bleeding.
A61B 17/24 - Surgical instruments, devices or methods for use in the oral cavity, larynx, bronchial passages or noseTongue scrapers
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 17/50 - Instruments for removing foreign bodies from the human body
A61M 29/02 - Inflatable dilatorsDilators made of swellable materials
41.
LOW ENERGY IMMUNE PRIMING FOR TREATING CANCER AND METASTASIS
Disclosed herein are the systems, devices and methods for treating cancer and metastasis using low energy immune priming. The low energy immune priming includes administering immunopriming energy. The low energy immune priming can be combined with an adjunct therapy.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
43.
Methods and devices for intraoperative viewing of patient 3D surface images
G06T 19/00 - Manipulating 3D models or images for computer graphics
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
G06T 7/68 - Analysis of geometric attributes of symmetry
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
A sterilizable device comprising electromagnetic transponders separated from one another by a flexible spacer material enclosed within radiofrequency-transparent sterilizable tubing for target tracking during prostate treatments, and method of use thereof.
Shaped liver biopsy sheaths and methods for transfemoral transcaval liver access are disclosed. The present invention provides methods of obtaining a tissue sample from the liver of a patient, the methods comprising inserting a hollow sheath, such as a stiffened sheath with an angled tip, through a femoral vein into a portion of the inferior vena cava (IVC) adjacent to the liver, wherein the sheath's tip is in the intrahepatic IVC and wherein the sheath has a shape that brings the tip of the sheath adjacent to the wall of the IVC at an angle that is optimal to allow penetration of the wall of the IVC by a biopsy needle, and inserting a biopsy needle through the sheath and through the wall of the NC into the liver to obtain a tissue sample from the liver.
Catheters and methods for controlling bleeding in airways and for occlusion of airways are provided that allow a bronchoscope to be withdrawn from the airway while an inflated balloon catheter remains in position in the airway, for example at a site of airway bleeding.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/958 - Inflatable balloons for placing stents or stent-grafts
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
MONTEFIORE MEDICAL CENTER (USA)
THE KITASATO INSTITUTE (USA)
NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (USA)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert C.
Nishi, Nozomu
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
A61Q 7/00 - Preparations for affecting hair growth
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The Board of Trustees of the University of Arkansas (USA)
The Kitasato Institute (Japan)
Montefiore Medical Center (USA)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert C.
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
50.
METHODS AND DEVICES FOR INTRAOPERATIVE VIEWING OF PATIENT 3D SURFACE IMAGES
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G06T 15/00 - 3D [Three Dimensional] image rendering
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
Surgical implants and methods are disclosed for promoting adhesion of tissue layers, where the implants comprise a longitudinal body, one or more clusters of projections extending from the body of the implant, and a hook on the end of the projection that is distal to the body of the implant, and where application of external pressure on the tissue at the site of the surgical implant causes the hooks on the ends of the projections to pierce the tissue layers and hold them together.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
Shaped liver biopsy sheaths and methods for transfemoral transcaval liver access are disclosed. The present invention provides methods of obtaining a tissue sample from the liver of a patient, the methods comprising inserting a hollow sheath, such as a stiffened sheath with an angled tip, through a femoral vein into a portion of the inferior vena cava (IVC) adjacent to the liver, wherein the sheath's tip is in the intrahepatic IVC and wherein the sheath has a shape that brings the tip of the sheath adjacent to the wall of the IVC at an angle that is optimal to allow penetration of the wall of the IVC by a biopsy needle, and inserting a biopsy needle through the sheath and through the wall of the IVC into the liver to obtain a tissue sample from the liver.
Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.
Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
60.
Delivery of therapeutic agents by a collagen binding protein
The Board of Trustees of the University of Arkansas (USA)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert C.
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
C07K 14/635 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
61.
Delivery of therapeutic agents by a collagen binding protein
National University Corporation Kagawa University (Japan)
Montefiore Medical Center (USA)
The Board of Trustees of the University of Arkansas (USA)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert C.
Nishi, Nozomu
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 8/65 - CollagenGelatinKeratinDerivatives or degradation products thereof
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
C07K 14/635 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61Q 7/00 - Preparations for affecting hair growth
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.
A method is provided for placing an epicardial pacing lead onto the epicardium of a heart in a subject. A method is also provided for placing an ablation catheter onto the epicardium of a heart in a subject. Articles of manufacture or machines for use in the methods are also provided.
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
MANAGED CARE SERVICES, NAMELY, ELECTRONIC PROCESSING OF PRE-PAID MANAGED HEALTH CARE PLAN AND LONG TERM HEALTH INSURANCE HEALTH CARE INFORMATION OF ELIGIBLE RECIPIENTS ADMINISTRATION OF PRE-PAID MANAGED HEALTH CARE PLANS; INSURANCE SERVICES, NAMELY, ADMINISTRATION OF LONG TERM HEALTH INSURANCE MANAGED HEALTH CARE SERVICES, NAMELY, PROVIDING FULLY INTEGRATED DUAL ADVANTAGE HEALTH CARE SERVICES TO ELIGIBLE RECIPIENTS
65.
Methods and devices for crosslinking of corneal collagen and for treatment of disorders of the eye
Methods and devices for delivering therapeutic or diagnostic energy (e.g., light, ultrasound, ionizing radiation (e.g., x-ray), vibration, heat energy, etc.) into the eye. An energy emitting device is positioned on the eye and used to deliver energy into the eye. The device may be constructed to allow the subject's eyelids to open and close while the device is positioned on the eye. The device is useable for various energy based or energy-mediated therapies, including crosslinking of corneal collagen, light therapy, photodynamic therapy, photo-activation of drugs, etc.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61F 9/008 - Methods or devices for eye surgery using laser
66.
DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
KITASATO UNIVERSITY (Japan)
MONTEFIORE MEDICAL CENTER (USA)
Inventor
Ponnapakkam, Tulasi
Philominathan, Sagaya, Theresa Leena
Sakon, Joshua
Katikaneni, Ranjitha
Koide, Takaki
Matsushita, Osamu
Gensure, Robert, C.
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (Japan)
MONTEFIORE MEDICAL CENTER (USA)
THE KITASATO INSTITUTE (Japan)
Inventor
Sakon, Joshua
Philominathan, Sagaya Theresa Leena
Katikaneni, Ranjitha
Matsushita, Osamu
Ponnapakkam, Tulasi
Koide, Takaki
Gensure, Robert C.
Nishi, Nozomu
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61P 5/20 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
68.
DELIVERY OF THERAPEUTIC AGENTS USING BACTERIAL COLLAGEN-BINDING POLYPEPTIDE SEGMENTS
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
MONTEFIORE MEDICAL CENTER (USA)
THE KITASATO INSTITUTE (Japan)
NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (Japan)
Inventor
Sakon, Joshua
Philominathan, Sagaya Theresa Leena
Katikaneni, Ranjitha
Matsushita, Osamu
Ponnapakkam, Tulasi
Koide, Takaki
Gensure, Robert, C.
Nishi, Nozomu
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (USA)
KITASATO UNIVERSITY (Japan)
MONTEFIORE MEDICAL CENTER (USA)
Inventor
Sakon, Joshua
Philominathan, Sagaya, Theresa, Leena
Katikaneni, Ranjitha
Matsushita, Osamu
Ponnapakkam, Tulasi
Koide, Takaki
Gensure, Robert, C.
Abstract
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
Disclosed are methods of obtaining an expanded population of mammalian ex vivo cells for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested or left at the engraftment site. Methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury are also described.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
MONTEFIORE MEDICAL CENTER (USA)
Inventor
Gertler, Frank, B.
Burge, Christopher, Boyce
Shapiro, Irina, M.
Cheng, Wu, Albert
Condeelis, John, S.
Oktay, Maja, H.
Abstract
The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and /or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.
Methods and compositions are disclosed for treating a subject with a disease or tissue injury mediated by cellular oxidative stress or with an environmental toxicity due to an electrophilic toxicant or pollutant, and for providing a nutritional supplement to a subject and for providing a skin treatment for a subject, where the methods comprise administering to the subject a 1,3-dicarbonyl compound.
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
74.
METHODS AND DEVICES FOR CROSSLINKING OF CORNEAL COLLAGEN AND FOR TREATMENT OF DISORDERS OF THE EYE
Methods and devices for delivering therapeutic or diagnostic energy (e.g., light, ultrasound, ionizing radiation (e.g., x-ray), vibration, heat energy, etc.) into the eye. An energy emitting device is positioned on the eye and used to deliver energy into the eye. The device may be constructed to allow the subject's eyelids to open and close while the device is positioned on the eye. The device is useable for various energy based or energy-mediated therapies, including crosslinking of corneal collagen, light therapy, photodynamic therapy, photo-activation of drugs, etc.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
A scaled head frame positioner and tabletop adapter are provided. The positioner may be employed for any neurosurgical procedure that requires fixed positioning of the stereotactic head frame or ring onto a patient's skull. The positioner employs a generally triangular shaped member with Velcro tapes fixed at each corner. The tapes have measurement markings, such as measurement tapes. The positioner supports the head frame with the tapes engaging means on the frame and fastened back to themselves, with markings indicating distances to adjust the position of the frame about the patient's head. Furthermore, the tabletop adapter clamps the patient with a stereotactic head frame onto a CT or treatment table. The tabletop adapter includes a generally U-shaped bracket secured to a support to be placed on the tabletop. The bracket is attachable to the head frame of the patient to hold his head in a desired position.
A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
A61B 17/00 - Surgical instruments, devices or methods
A61F 4/00 - Methods or devices enabling patients or disabled persons to operate an apparatus or a device not forming part of the body
A61F 5/04 - Devices for stretching or reducing fractured limbsDevices for distractionsSplints
76.
Hypoxic conditioning in patients with exercise limiting conditions
Patients having exercise limiting conditions and those at risk of developing such conditions are exposed to a regimen of hypoxic conditions that simulate various altitude conditions. The exposure is of a temporary nature, being from a few hours to most of a day or night in any one day and repeated on a personally worked out regimen of from a series of consecutive days to a regular number of “on” and “off” days, to a random number of days. An alternate regimen is such exposure for a few minutes at a time followed by normoxic rest period of a few minutes, with the cycle repeated multiple times over the course of a treatment session. The conditioning treatment strengthens the cardiac tissue and skeletal muscle and the results extend beyond the treatment periods whereby the patient's condition is substantially improved.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
MONTEFIORE MEDICAL CENTER (USA)
Inventor
Singer, Robert, H.
Pezo, Rossanna
Augenlicht, Leonard, H.
Abstract
The present invention generally relates to methods for determining tumor resistance or sensitivity to chemotherapeutic agents and the likelihood of tumor reoccurrence based on the expression levels of genes known to correlate to the chemotherapeutic agent. In particular, the expression levels of TYMS, MRGX, ATP7B and/or BAK in tumor cells, as measured by the number of active transcription sites detected by fluorescence in situ hybridization (FISH), are predictive of resistance and sensitivity to chemotherapy and the likelihood of reoccurrence following chemotherapy treatment.
Attachments for a manual wheelchair are provided for navigating a wheelchair over obstacles and uneven terrain, such as a typical curb on a street. The attachments provide for regulating the movement of the wheelchair as the wheelchair descends the curb and to prevent the wheelchair from flipping over during such movement. The attachments include a front caster wheel slider assembly on each side of the wheelchair, a follower wheel assembly and a track belt damping bar. The front caster wheel slider assembly includes a piston that will quickly push the front caster wheels down after they roll over the top edge of the curb. The follower wheel assembly acts as a sensor that will release the piston in the assembly after the front caster wheels roll over the top edge of the curb. As the back wheels of the wheelchair roll over and down the curb, the track belt damping bar slows the descent of the wheelchair.
A61G 5/06 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs with obstacle-mounting facilities, e.g. for climbing stairs
B62B 5/02 - Accessories or details specially adapted for hand carts providing for travelling up or down a flight of stairs
79.
PREPARATIVE REGIMEN FOR ENGRAFTMENT, GROWTH AND DIFFERENTIATION OF NON-HEMATOPOEITIC CELLS IN VIVO
The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested for further use or be left at the engraftment site of a subject to be treated. The invention also provides methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury.
Attachments for a manual wheelchair arc provided for navigating a wheelchair over obstacles and uneven terrain, such as a typical curb on a street, 'The attachments provide for regulating the movement of the wheelchair as the wheelchair descends the curb and to prevent the wheelchair from flipping over during such movement. The attachments include a front caster wheel slider assembly on each side of the wheelchair, a follower wheel assembly and a track belt damping bar. The from caster wheel slider assembly includes a piston that will quickly push the front caster wheels down after they roil over the top edge of the curb. The follower wheel assembly acts a sensor that will release the piston in the assembly after the front caster wheels roll over the top edge of the curb. As the back wheels of the wheelchair roll over and down the curb, the track belt damping bar slows the descent of the wheelchair.
A61G 5/06 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs with obstacle-mounting facilities, e.g. for climbing stairs
Systems and methods are provided for facilitating management of health care in medical facilities such as hospitals, clinics, emergency rooms, etc., for example by monitoring and assessing the quality of patient care. Data is collected and operated on relating to medical conditions, treatment, cost, care, events, outcomes and results of treatments, and data representing the collective experience of similar patients is mined to discover opportunities to improve the quality of health care. Statistical and comparative data and reports including such and other information indicate a quality of care and provide epidemiologically cogent information. Quality of care may be considered as achieving desired or expected norms of performance, including success, in a timely fashion, and can be judged not just by what functionally happens during a patient instigated encounter, but also by long term outcomes evidenced by the patient's passage through the health care delivery system.
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
